Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
February 15, 2019

SK, Arvelle sign $530m deal for antiepileptic drug cenobamate

SK Biopharmaceuticals has entered into a $530m deal with the Arvelle Therapeutics for investigational antiepileptic drug cenobamate.

Image: SK, Arvelle have signed $530m deal for investigational antiepileptic drug cenobamate. Photo: courtesy of rawpixel / Unsplash.